INTRODUCTION: The objective of this article is to establish guidelines proposed by the external genital organ group of the CCAFU for the diagnosis, treatment and follow-up of the germ cell tumours of the testis.
MATERIAL AND METHODS: The multidisciplinary working party studied previous guidelines, exhaustively reviewed the literature, and evaluated references and their level of proof in order to attribute grades of recommendation.
RESULTS: The initial work-up of testicular cancer is based on clinical, laboratory (AFP, total hCG, LDH) and imaging assessment (scrotal ultrasound and chest, abdomen and pelvis computed tomography). Inguinal orchidectomy is the first-line treatment allowing characterization of the histological type, local staging and identification of risk factors for micrometastases. The management of stage I tumours must be adapted to the risk by explaining to the patient the benefits/disadvantages of active treatment or watchful waiting as a function of the risk of relapse. Treatment options for stage 1 seminomas comprise : watchful waiting, chemotherapy (1 cycle of carboplatin) or para-aortic radiotherapy. Treatment options for stage 1 nonseminomatous germ cell tumours comprise : watchful waiting, chemotherapy (2 cycles of BEP) or staging retroperitoneal lymphadenectomy. The management of metastatic tumours essentially comprises chemotherapy with 3 or 4 cycles of BEP according to the prognostic group. Radiotherapy may be indicated in seminomas with lymph node metastasis < 3cm. Review 3 to 4 weeks post-chemotherapy is essentially based on tumour marker assays and chest, abdomen and pelvis computed tomography. Surgical retroperitoneal lymph node dissection is indicated for all residual NSGCT masses > 1cm and for persistent residual seminoma masses > 3cm with 18F-FDG PET-CT uptake.
CONCLUSIONS: Germ cell tumours have an excellent survival rate based on precise initial staging, adapted and strictly defined treatment and close surveillance.
Written by:
Durand X, Rigaud J, Avancès C, Camparo P, Fléchon A, Murez T, Sèbe P, Culine S, Iborra F, Mottet N, Coloby P, Soulié M. Are you the author?
Membres du CCAFU-OGE (Comité de cancérologie de l'Association française d'urologie - sous-comité Organes génitaux externes et rétropéritoine); Membres experts du CCAFU-OGE (Comité de cancérologie de l'Association française d'urologie - sous-comité Organes génitaux externes et rétropéritoine).
Reference: Prog Urol. 2013 Nov;23 Suppl 2:S145-60.
doi: 10.1016/S1166-7087(13)70052-6
PubMed Abstract
PMID: 24485289
Article in French.
UroToday.com Testicular Cancer Section
